70
Emergent BioSolutions Inc. (EBS): CFO Richard Lindahl retired; interim named
EBS · NYSE · Pharmaceutical Preparations · Accelerated filer · MD · Form 8-K filed 2026-10-16
Richard Lindahl steps down as CFO effective December 31, 2026, retiring March 31, 2027; Frank Vargo appointed Interim CFO effective January 1, 2027.
Open seatNo successor namedInterim in placePrincipal officerPlanned transitionNew budget ownerExternal hireInterim appointment
Events in this filing
3 events: Departure (CFO), Retirement announced (CFO), Appointment (CFO).
Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans
Item 5.02 as filed
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2026, Emergent BioSolutions Inc. (the “ Company ”) announced that Richard Lindahl, the Company’s Chief Financial Officer, will step down from his role as the Company’s principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027. The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company’s Interim Chief Financial Officer and principal financial and accounting officer beginning on January 1, 2027. Prior to his retirement date, Mr. Lindahl will assist with the transition of his responsibilities, including the preparation and filing of the Company’s Annual Report on Form 10-K for the year ending December 31, 2026. Mr. Lindahl’s compensation as an advisor will be materially consistent with his current compensation. The Company thanks Mr. Lindahl for over eight years of dedicated service to the Company as its Chief Financial Officer. Frank Vargo, age 43, joined the Company in December 2019 as Director, Corporate FP&A and G&A. Mr. Vargo was named Vice President, Treasurer in November 2025. Prior to joining the Company, Mr. Vargo held roles of increasing responsibility in finance at Under Armor, Inc. and in the aerospace and defense industry. He holds an MBA from Texas A&M University and a bachelor’s degree in engineering from the Georgia Institute of Technology. In connection with his promotion to Interim Chief Financial Officer, the Company’s Board of Directors approved interim compensation pay of an additional $3,850 per pay period in addition to his current base salary of $328,000 for Mr. Vargo commencing January 1, 2027. Mr. Vargo’s salary, bonus and equity awards will remain commensurate with his seniority and position before his appointment as Interim Chief Financial Officer and will be reviewed on the same cycle as those of the Company’s other Emergent executive officers. Mr. Vargo and his immediate family members are not party to any related party transactions for which disclosure would be required pursuant to Item 404(a) of Regulation S-K. There is no family relationship between Mr. Vargo and any of the Company’s directors or executive officers and no arrangements or understandings with other persons pursuant to which Mr. Vargo was selected as an officer. A copy of our press release (the “ Press Release ”), dated October 16, 2026, announcing the transition is filed hereto as Exhibit 99.1 and is incorporated herein by reference.Source filing on EDGAR →